PILOT STUDY OF ATOMOXETINE TO ENHANCE COGNITION IN PATIENTS WITH SCHIZOPHRENIA
PILOT STUDY OF ATOMOXETINE TO ENHANCE COGNITION IN PATIENTS WITH SCHIZOPHRENIA
批准号:
7380539
负责人:
JOSEPH H FRIEDMAN
金额:
$0.64万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-17 至 2007-02-28
中文摘要
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。尽管阳性症状得到了充分的控制,但许多精神分裂症患者仍存在严重的认知缺陷,这限制了他们实现最佳功能能力的能力。增强前额叶皮层多巴胺能活性的药物可能是改善认知而不加重精神病的理想药物。临床前研究表明,托莫西汀可以增加前额叶皮层的多巴胺水平,但在皮层下区域,如纹状体和伏隔核,则不会增加多巴胺水平。因此,我们相信,当加入稳定的抗精神病药物治疗方案时,它可能非常有用,可以增强精神分裂症患者的认知能力。在本研究中,我们将在功能磁共振成像(fMRI)期间对精神分裂症和分裂情感性障碍患者进行基线神经认知测试,并通过工作记忆测试测量前额叶皮层的激活。然后,患者将随机接受阿托西汀或安慰剂,以及常规剂量的抗精神病药物。托莫西汀的起始剂量为每天40毫克,四周后增加到40毫克,然后在接下来的四周继续使用这个剂量。在4周和8周的治疗后,将进行重复的神经认知测试,只有在8周的治疗后才会重复功能磁共振成像。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite adequate control of positive symptoms, many patients with schizophrenia suffer from severe cognitive deficits that limit their ability to realize optimal functional capacity. Medications that enhance dopaminergic activity in the prefrontal cortex may be ideal to improve cognition without worsening psychosis. Atomoxetine has been shown in pre-clinical studies to increase dopamine levels in prefrontal cortex but not in subcortical regions such as striatum and nucleus accumbens. Therefore, we believe that it may be extremely useful, when added to a stable regimen of antipsychotic medication, in enhancing cognition in patients with schizophrenia. In the proposed study, we will conduct baseline neurocognitive tests and measure activation of the prefrontal cortex by a working memory test during functional magnetic resonance imaging (fMRI) in patients with schizophrenia and schizoaffective disorder. Patients will then be randomized to receive either atomoxetine or placebo in addition to their regular dose of antipsychotic medication. The starting dose of atomoxetine will be 40 mg per day which will be increased to 40 mg bid after four weeks and then continued at this dose for the next four weeks. After four and eight weeks of treatment, repeat neurocognitive tests will be conducted and the fMRI will be repeated only after eight weeks of treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Center for the Parkinson Disease Neuroprotection Clinical Trial
-
批准号:7239571
-
项目类别:
-
资助金额:$2.7万
-
财政年份:2006
-
负责人:JOSEPH H FRIEDMAN
-
依托单位:
海外基金